GLP-1 For Lab Research

GLP-1 (Glucagon-Like Peptide-1) – High-Purity Incretin Hormone Research Peptide | Peptides Lab UK

GLP-1 (Glucagon-Like Peptide-1) is a 30-amino acid incretin hormone derived from the proglucagon gene, secreted by intestinal L-cells in response to nutrient ingestion, that acts via the GLP-1 receptor (GLP-1R) to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce food intake — supplied by Peptides Lab UK in lyophilised format at >99% purity (HPLC verified) for in vitro and pre-clinical laboratory research use only.

Available to buy in the UK from Peptides Lab UK, GLP-1 is one of the most extensively researched peptide hormones in modern biomedical science — the foundational molecule behind an entire class of GLP-1 receptor agonist (GLP-1RA) drugs including semaglutide, liraglutide, and dulaglutide, which together represent one of the fastest-growing areas in pharmaceutical research. As the native peptide, GLP-1 provides the reference pharmacological standard for all GLP-1R binding, signalling, and pathway studies. Each batch is independently quality-tested and distributed in a controlled lyophilised format, suitable for precise laboratory handling and in vitro research protocols.

What is GLP-1 (Glucagon-Like Peptide-1)?

GLP-1 is a 30-amino acid peptide hormone produced by differential post-translational processing of the proglucagon precursor protein by prohormone convertase 1/3 (PCSK1) in intestinal L-cells and in neurons of the nucleus tractus solitarii (NTS) in the brainstem. The proglucagon gene encodes a 180-amino acid precursor that, depending on the tissue-specific expression of processing enzymes, yields different active peptides: in the pancreatic alpha cells, PCSK2 processing produces glucagon; in the intestinal L-cells and brain, PCSK1 processing produces GLP-1 and GLP-2 as part of a larger proglucagon fragment.

The primary bioactive form of GLP-1 is GLP-1(7–36)amide — a 30-amino acid C-terminally amidated peptide. Smaller amounts of the non-amidated GLP-1(7–37) are also produced. Both forms are biologically active at the GLP-1 receptor, though GLP-1(7–36)amide is the predominant circulating form in published pharmacokinetic literature. A key challenge in studying native GLP-1 is its extremely short in vivo half-life of approximately 1–2 minutes, owing to rapid inactivation by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal His-Ala dipeptide from GLP-1 to produce the inactive metabolite GLP-1(9–36)amide. This rapid degradation is the primary reason that GLP-1 receptor agonist drugs require structural modifications — such as DPP-4 resistance mutations, albumin binding, or Fc fusion — to achieve a pharmacologically useful duration of action.

GLP-1 is released from intestinal L-cells in a biphasic pattern following meal ingestion: an initial early peak within 10–15 minutes, driven primarily by neural and endocrine signals from the upper gastrointestinal tract, is followed by a sustained second peak at 30–60 minutes driven by direct nutrient contact with L-cells in the distal ileum and colon. Circulating plasma GLP-1 levels rise from approximately 5–10 pmol/L in the fasted state to 15–50 pmol/L in the postprandial state, with peak levels depending on meal composition, caloric density, and rate of gastric emptying.

GLP-1 – Key Research Facts

• Full name: Glucagon-Like Peptide-1 — incretin hormone of the proglucagon family
• Primary bioactive form: GLP-1(7–36)amide — 30 amino acids, C-terminally amidated
• Gene source: Proglucagon gene — processed by PCSK1 in intestinal L-cells and brainstem NTS neurons
• In vivo half-life: Approximately 1–2 minutes — rapidly inactivated by DPP-4 (cleaves His7-Ala8 dipeptide)
• Primary receptor: GLP-1R (GLP-1 receptor) — class B G protein-coupled receptor (GPCR)
• Signalling: GLP-1R activation → cAMP elevation → PKA/CREB activation → glucose-dependent insulin secretion
• Additional signalling: PI3K/Akt pathway — β-cell survival, proliferation, and glucose sensitivity
• Secretion pattern: Biphasic post-meal release from intestinal L-cells — early neural/endocrine peak + late direct nutrient-contact peak
• Fasting plasma level: ~5–10 pmol/L; postprandial peak: ~15–50 pmol/L
• Research significance: Native reference peptide for all GLP-1R binding, signalling, and incretin pathway studies — foundational molecule for semaglutide, liraglutide, and dulaglutide drug class

What Does GLP-1 Do in Research?

In laboratory and pre-clinical research settings, native GLP-1 serves as the primary pharmacological reference standard for studying GLP-1 receptor binding, activation, and downstream signalling — as well as the broader incretin axis and its connections to pancreatic β-cell biology, appetite regulation, gastric motility, cardiovascular function, and neuroprotection. GLP-1 research spans a remarkably broad range of biological systems owing to the widespread distribution of the GLP-1 receptor across multiple tissue types.

At the cellular level, GLP-1 binding to GLP-1R activates the Gs protein, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple targets including ion channels, transcription factors (notably CREB), and components of the insulin secretory machinery. In pancreatic β-cells, this results in enhanced glucose-dependent insulin exocytosis — the ‘incretin effect’ — and also drives insulin gene expression and β-cell survival and proliferation via the PI3K/Akt pathway. The glucose-dependency of GLP-1’s insulinotropic effect — it only amplifies insulin secretion when blood glucose is elevated — is a key pharmacological property that distinguishes GLP-1 from non-incretin insulin secretagogues in research models.

Beyond the pancreas, GLP-1R is expressed in the brain (particularly the hypothalamus, brainstem NTS, and reward circuitry), heart, kidney, lung, gastrointestinal tract, bone, and immune cells. This broad receptor distribution underlies the pleiotropic research profile of GLP-1 — from appetite and reward behaviour regulation in the central nervous system, to cardioprotective effects in cardiac tissue, to anti-inflammatory and immunomodulatory activity in immune cell models. The native GLP-1 peptide provides the most direct tool for interrogating all of these receptor-mediated pathways at source, without the confounding structural modifications present in GLP-1RA drug compounds.

Key Research Areas for GLP-1

• GLP-1R binding kinetics, receptor occupancy, and competition assays — reference ligand for GLP-1RA drug development
• cAMP/PKA/CREB intracellular signalling cascade studies in pancreatic β-cell models
• PI3K/Akt β-cell survival, proliferation, and apoptosis pathway research
• Glucose-dependent insulin secretion assays — incretin effect characterisation in isolated islet and β-cell models
• Glucagon suppression pathway studies in pancreatic α-cell and islet co-culture models
• DPP-4 degradation kinetics and GLP-1 metabolite (GLP-1(9–36)amide) pathway studies
• Central nervous system appetite regulation — hypothalamic GLP-1R signalling and energy homeostasis research
• Reward behaviour and dopaminergic signalling pathway investigations — hedonic eating models
• Cardiovascular pathway research — cardioprotection, heart rate regulation, and GLP-1R-positive cardiac cell studies
• Gastric emptying and gastrointestinal motility pathway studies — ‘ileal brake’ mechanism research
• Anti-inflammatory and immune cell GLP-1R signalling studies — T-cell, macrophage, and lymphocyte models
• Neuroprotection pathway research in neuronal cell models
• Comparative GLP-1 vs. GLP-1RA potency, duration, and receptor engagement studies
• Multi-agonist research context — GLP-1 as the reference arm in GIP/GLP-1 and GLP-1/GCG/GIP triple agonist studies

What Do Studies Say About GLP-1?

GLP-1 has one of the most extensive published research bases of any peptide hormone in modern biomedical science, with thousands of peer-reviewed studies spanning its discovery, physiology, receptor pharmacology, and the entire GLP-1RA drug class built upon it.

Foundational GLP-1 Physiology Review (PubMed, 2007)

GLP-1 as Incretin, Enterogastrone, and Appetite Regulator — Establishing the Full Physiological Profile

A comprehensive review of GLP-1 physiology published on PubMed confirmed that GLP-1 is a 30-amino acid peptide hormone produced in intestinal L-cells by differential processing of proglucagon, released in response to meal intake. The review documented GLP-1’s rapid inactivation by DPP-4 even before the hormone has left the gut — raising the hypothesis that GLP-1’s actions may be partially transmitted via sensory neurons in the intestine and liver expressing the GLP-1 receptor rather than solely through systemic endocrine circulation. The main confirmed actions were documented as: stimulating insulin secretion (incretin effect), inhibiting glucagon secretion, inhibiting gastrointestinal motility and secretion (enterogastrone / ileal brake mechanism), and regulating appetite and food intake. The review also noted that decreased GLP-1 secretion may contribute to obesity development, and that exaggerated secretion may be responsible for postprandial reactive hypoglycaemia.

Reference: Holst JJ (2007). The physiology of glucagon-like peptide 1. Physiological Reviews. PubMed PMID: 17928588.

Multi-System GLP-1 Pharmacology & Therapeutic Applications Review (PubMed, 2019)

GLP-1’s Pleiotropic Receptor Distribution Across Pancreas, Brain, Heart, and Gut

A major review of GLP-1’s multifaceted pharmacology published on PubMed confirmed GLP-1’s broad pharmacological potential across multiple systems. The review documented the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, natriuresis and diuresis, and modulation of β-cell proliferation as key pancreatic and gastrointestinal actions. The review also confirmed GLP-1’s cardioprotective and neuroprotective effects, its ability to decrease inflammation and apoptosis, and its roles in learning and memory, reward behaviour, and food palatability via central GLP-1R-expressing circuits. The development of GLP-1 receptor agonists for type 2 diabetes was contextualised within the broader research landscape, including orally bioavailable agonists, allosteric modulators, and unimolecular multi-agonists — all of which use the native GLP-1 receptor as their primary target.

Reference: Müller TD et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. PubMed PMID: 31767182.

GLP-1R Mechanisms & Advances in Therapy Review (Signal Transduction & Targeted Therapy, 2024)

Full Receptor Biology from β-Cell cAMP Signalling to Multi-System Pleiotropic Effects

A comprehensive review of GLP-1R mechanisms and therapeutic advances published in Signal Transduction and Targeted Therapy (Nature Publishing Group, 2024) documented the full receptor biology of GLP-1R — a class B GPCR found on the surface of multiple cell types. In β-cells, GLP-1(9–36) activates GLP-1R, increasing cAMP and activating PKA and CREB to promote insulin secretion; the PI3K/Akt pathway enhances glucose sensitivity and supports β-cell survival. The review confirmed GLP-1R is expressed at high levels on δ-cells, where GLP-1 stimulates somatostatin secretion — which in turn indirectly suppresses both glucagon and insulin through paracrine mechanisms. The review traced the developmental history of GLP-1 research from the identification of the proglucagon gene in 1982 through to the contemporary landscape of GLP-1-based therapeutics across obesity, cardiovascular disease, NAFLD, neurodegeneration, and cancer biology.

Reference: Cui C et al. (2024). Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. DOI: 10.1038/s41392-024-01931-z. PubMed PMID: 39289339.

GLP-1 & GIP Mechanisms — Incretin Comparative Review (PubMed, 2024)

Two-Incretin Model: GLP-1 and GIP Receptor Signalling Across Pancreas, Brain, Liver, and Adipose Tissue

A comparative review of GLP-1 and GIP receptor mechanisms published on PubMed in 2024 documented the complete receptor-level biology of both incretins across multiple tissues. For GLP-1, the review confirmed insulinotropic effects on β-cells during hyperglycaemia, glucagonostatic effects on α-cells during hyperglycaemia (indirect, via somatostatin and insulin), gastric emptying delay, CNS appetite suppression, and indirect promotion of lipolysis via increased sympathetic activity. The review contextualised native GLP-1 as the reference molecule for the entire dual GIP/GLP-1 receptor agonist research field — including tirzepatide (approved) and novel triple agonists targeting GLP-1R, GIPR, and GCGR simultaneously — confirming native GLP-1’s ongoing research importance as the pharmacological anchor of this rapidly expanding compound class.

Reference: Willard FS et al. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Nature Reviews Drug Discovery. PubMed PMID: 39114288.

GLP-1RA Reward Behaviour Systematic Review (PubMed, 2024)

GLP-1 Receptor Signalling in Reward Circuitry, Dopamine, and Addiction Research

A systematic review of GLP-1 receptor agonist effects on reward behaviour published on PubMed — following PRISMA guidelines across OVID, PubMed, Scopus, and Google Scholar — evaluated the evidence for GLP-1R’s role in reward dysfunction across obesity, type 2 diabetes, and psychiatric conditions. The review confirmed that GLP-1RAs consistently reduced energy intake and influenced reward-related behaviour across human studies. GLP-1RAs were documented to normalise insulin resistance and modulate dopaminergic signalling — reducing anhedonia and influencing food cue reactivity. The effects on glycaemic variability and cravings were noted as suggesting potential research applications in addiction disorder models. The review concluded that GLP-1R signalling in reward circuitry represents a significant, underexplored research territory for the native GLP-1 peptide and its analogues.

Reference: Haddad PM et al. (2024). Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review. Journal of Psychopharmacology. PubMed PMID: 38945189.

GLP-1RA Mechanisms of Action Review — Islet Function, Appetite, Inflammation & Cardiovascular (Cell Metabolism, 2018)

Native GLP-1 Circuits vs. Pharmacological GLP-1RA Action — Key Mechanistic Distinctions

A comprehensive review published in Cell Metabolism reviewed circuits engaged by endogenous versus pharmacological GLP-1 action, highlighting key GLP-1R-positive cell types and pathways transducing metabolic and non-glycaemic GLP-1 signals. The review covered GLP-1’s roles in controlling islet function, appetite, inflammation, and cardiovascular pathophysiology, and made a critical mechanistic distinction: native GLP-1 acts primarily via paracrine and neural mechanisms (given its 1–2 minute plasma half-life), whereas GLP-1RA drugs with extended half-lives act systemically on GLP-1R populations inaccessible to the native peptide. This distinction has direct implications for in vitro receptor research — native GLP-1 provides a physiologically authentic agonist reference for local/paracrine GLP-1R signalling studies, distinct from the systemic receptor engagement profile of long-acting GLP-1RA analogues.

Reference: Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. DOI: 10.1016/j.cmet.2018.01.027. PubMed PMID: 29617641.

GLP-1 UK – Specifications

Product Details

• Full name: Glucagon-Like Peptide-1 (GLP-1(7–36)amide — primary bioactive form)
• Peptide length: 30 amino acids
• Purity:>99% (HPLC verified)
• Form: Lyophilised powder
• Storage: Store dry at –20°C; protect from light
• Solubility: Sterile water, bacteriostatic water, or suitable laboratory buffer
• Distributed by: Peptides Lab UK
• Quality assurance: Rigorous batch-level analysis; certificate of analysis available on request

Research Applications

Suitable Laboratory Uses for GLP-1

• GLP-1R binding kinetics, receptor occupancy, and displacement assays — primary reference ligand
• cAMP/PKA/CREB signalling cascade studies in pancreatic β-cell and islet models
• PI3K/Akt β-cell survival, proliferation, and anti-apoptotic pathway research
• Glucose-dependent insulin secretion and incretin effect characterisation assays
• Glucagon suppression and α-cell / δ-cell paracrine signalling pathway studies
• DPP-4 degradation kinetics and GLP-1(9–36)amide metabolite pathway research
• CNS appetite regulation — hypothalamic and brainstem GLP-1R circuit studies
• Dopaminergic reward signalling and hedonic eating pathway investigations
• Cardiovascular GLP-1R pathway and cardioprotection studies
• Anti-inflammatory and immune cell GLP-1R signalling research
• Neuroprotection pathway studies in neuronal cell models
• Comparative native GLP-1 vs. GLP-1RA receptor engagement and potency studies
• Multi-agonist reference arm research — GLP-1/GIP, GLP-1/GCG, and triple agonist studies
• Molecular analysis and controlled laboratory experiments

Why Buy GLP-1 Peptide in the UK from Peptides Lab UK?

Peptides Lab UK is a trusted UK-based supplier of research-grade peptides. All products are distributed in lyophilised format with batch-verified purity documentation. Whether you are looking to buy GLP-1 peptide in the UK, sourcing native Glucagon-Like Peptide-1 as a receptor reference standard for GLP-1R research, or searching for a reliable UK peptides supplier with documented quality control, Peptides Lab UK provides consistent quality with rigorous third-party analysis on every batch.

As the native reference peptide for the entire GLP-1 receptor agonist drug class — a research field now spanning semaglutide, liraglutide, dulaglutide, tirzepatide, and retatrutide — verified, high-purity GLP-1 is an essential research tool for any laboratory conducting GLP-1R binding, signalling, or comparative pharmacology studies. The >99% HPLC-verified purity standard applied to Peptides Lab UK’s GLP-1 preparation ensures that receptor binding data and cAMP assay results reflect authentic GLP-1R pharmacology without interference from impurities or truncated inactive metabolites.

Related Search Terms

Researchers searching for: buy GLP-1 UK, GLP-1 peptide UK, Glucagon-Like Peptide-1 UK research, GLP-1 for sale UK, native GLP-1 UK, GLP-1 research peptide UK, UK peptides research grade, Peptides UK lab supply, GLP-1 receptor agonist reference peptide UK, incretin peptide UK, buy GLP-1(7-36) UK, GLP-1 in the UK, GLP1 peptide UK, cAMP signalling peptide UK, incretin research compound UK — Peptides Lab UK supplies this compound for qualified laboratory researchers within the United Kingdom.

Important Notice & Research Disclaimer

⚠️ This product is supplied by Peptides Lab UK strictly for laboratory research use only. GLP-1 (Glucagon-Like Peptide-1) as distributed by Peptides Lab UK is not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment. This compound is handled exclusively in controlled research settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine.

Handling must only be performed by qualified and trained laboratory professionals in accordance with applicable regulations and institutional guidelines. Peptides Lab UK accepts no liability for any use of this compound outside of its intended laboratory research purpose.

References to published research throughout this description are provided for informational and research context only and do not constitute medical claims or endorsements of any therapeutic application of this product.